A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf
.
Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation
2008
Haematologica
Antithymocyte globulin or human Jurkat T-cell-line-derived antilymphocyte globulin is used in allogeneic stem cell transplantation to induce in vivo T-cell depletion to facilitate engraftment and lower graft-versus-host disease. In vitro studies suggest that antithymocyte globulin, besides causing T-cell depletion, has strong anti-myeloma activity. Design and Methods We evaluated the anti-myeloma activity of antilymphocyte globulin in a melphalan/fludarabinebased reduced intensity conditioning
doi:10.3324/haematol.12665
pmid:18641030
fatcat:hkgvkhl5dzhr5m6xxp445x55ba